updated chart, page-1132

Great stuff Big Dan. You sure know how to convey not only the big picture prognosis (pardon the pun) but also capture the essence of our CEO's business model.

Eventho your passion is infectious, there's not much left for me to add except to say that the potential here with OmniCAR could be enormous. Just think of what could come out of the cell therapy enhancement program by way of patentable technologies (already we know of one)... additional patentable biomarkers perhaps too, etc... each of which could assume a place alongside Spycatcher and SpyTag for licensing.

There could be no limit to how many therapies, enhancements, diagnostic tools and binary products PTX can add to OmniCAR in growing it's suite. The platform concept definitely lends itself to expanding personalised medicines and therapies. The scope is enormous. And our guys have a distinct vision for something that is unique, holistic yet so simple!

It'll also earn us a revenue stream with which to finance endless R&D. How many new CarT therapies will PTX be able to trial and commercialise in the future whilst OmniCar chuggs along in the background earning bread and butter money?

Brilliant concept... and one that globally-renowned experts are willing to support and be involved in. I reckon it's going to be exciting being a part of this unfolding story!

Time for nigh, nighs! Sweet dreams